21:58 , Jul 17, 2018 |  BC Innovations  |  Product R&D

Natural spots

With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized niches on proteins that nature uses to control their activity. The company’s platform has identified druggable allosteric...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
18:57 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Dermira discontinues development of acne candidate

Dermira Inc. (NASDAQ:DERM) said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two double-blind, international Phase III trials to treat moderate to severe acne vulgaris. The company plans to discontinue development of the inhibitor...
18:33 , Mar 5, 2018 |  BC Extra  |  Clinical News

Dermira plummets after Phase III acne failure

Dermira Inc. (NASDAQ:DERM) slid $16.57 (66%) to $8.59 on Monday after it said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two Phase III trials to treat moderate to severe acne vulgaris. The company...
18:52 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Gilead reports mixed Phase II data for NASH candidate

Gilead Sciences Inc. (NASDAQ:GILD) reported data from a Phase II trial of GS-0976 to treat non-alcoholic steatohepatitis (NASH) showing that the higher of 2 doses of the compound significantly reduced liver fat content and a...
21:11 , Oct 24, 2017 |  BC Extra  |  Clinical News

Gilead reports mixed Phase II data for NASH candidate

Gilead Sciences Inc. (NASDAQ:GILD) reported mixed data from a Phase II trial of GS-0976 to treat non-alcoholic steatohepatitis showing that the higher of two doses of the compound significantly reduced liver fat content and a...
22:08 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Nimble move

Celgene Corp. ’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to...
19:05 , Jul 20, 2017 |  BC Innovations  |  Translation in Brief

Lethal logic

Following the success of the PARP inhibitors in the clinic, researchers are now rushing to find more synthetic lethal interactions that can be exploited for therapeutic or diagnostic uses. A Stanford University team has risen...
21:29 , May 4, 2017 |  BC Innovations  |  Tools & Techniques

Testing intelligence

An explosion in access to high-power hardware and deep computer learning has made companies like Atomwise Inc. confident that artificial intelligence (AI) can finally deliver on its decades-old promise to accelerate drug discovery. The company...